with WHIM syndrome The CXCR4 antagonist plerixafor corrects panleukopenia in patients
暂无分享,去创建一个
D. Kuhns | P. Murphy | R. Decastro | T. Fleisher | H. McDermott | Mary Garofalo | D. L. Priel | Jean Ulrick | Qian Liu | Corin Kelly | M. Marquesen | J. O. Filho | Patricia Littel | D. Hilligoss | Sandra Anaya-O | L. Malech
[1] D. McDermott,et al. AMD3100 is a potent antagonist at CXCR4R334X, a hyperfunctional mutant chemokine receptor and cause of WHIM syndrome , 2011, Journal of cellular and molecular medicine.
[2] R. Brunauer,et al. Human Bone Marrow Hosts Polyfunctional Memory CD4+ and CD8+ T Cells with Close Contact to IL-15–Producing Cells , 2011, The Journal of Immunology.
[3] S. Paul,et al. Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. , 2010, Blood.
[4] Kevin B. Walters,et al. Live imaging of neutrophil motility in a zebrafish model of WHIM syndrome. , 2010, Blood.
[5] C. Cunningham-Rundles,et al. Oligoclonality, impaired class switch and B-cell memory responses in WHIM syndrome. , 2010, Clinical immunology.
[6] A. Nademanee,et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization , 2010, Bone Marrow Transplantation.
[7] A. V. Gulino,et al. Impaired Recruitment of Grk6 and β-Arrestin2 Causes Delayed Internalization and Desensitization of a WHIM Syndrome-Associated CXCR4 Mutant Receptor , 2009, PloS one.
[8] A. Nademanee,et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Andreas Radbruch,et al. Professional memory CD4+ T lymphocytes preferentially reside and rest in the bone marrow. , 2009, Immunity.
[10] H. Malech,et al. WHIM syndrome: congenital immune deficiency disease , 2009, Current opinion in hematology.
[11] T. Grodzicki,et al. Familial occurrence of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome , 2008, Archivum Immunologiae et Therapiae Experimentalis.
[12] N. Naumann,et al. WHIM syndrome myelokathexis reproduced in the NOD/SCID mouse xenotransplant model engrafted with healthy human stem cells transduced with C-terminus-truncated CXCR4. , 2007, Blood.
[13] Alain Dupuy,et al. WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. , 2005, Blood.
[14] E. Wherry,et al. Bone Marrow Is a Preferred Site for Homeostatic Proliferation of Memory CD8 T Cells , 2005, The Journal of Immunology.
[15] Dominique Schols,et al. Safety, Pharmacokinetics, and Antiviral Activity of AMD3100, a Selective CXCR4 Receptor Inhibitor, in HIV-1 Infection , 2004, Journal of acquired immune deficiency syndromes.
[16] J. Cyster,et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5 , 2004, Nature Immunology.
[17] B. Wood,et al. Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist. , 2004, Supportive cancer therapy.
[18] B. Wood,et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. , 2003, Blood.
[19] S. Rankin,et al. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. , 2003, Immunity.
[20] R. Gorlin,et al. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease , 2003, Nature Genetics.
[21] T. Fleisher,et al. Diagnostic paradigm for evaluation of male patients with chronic granulomatous disease, based on the dihydrorhodamine 123 assay. , 2003, The Journal of allergy and clinical immunology.
[22] Edward J. Fuchs,et al. Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers , 2000, Antimicrobial Agents and Chemotherapy.
[23] T. Springer,et al. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. , 1999, Immunity.
[24] R. Bronson,et al. Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[25] Kouji Matsushima,et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.
[26] Masahiko Kuroda,et al. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development , 1998, Nature.
[27] E. Kleinerman,et al. A new familial immunodeficiency disorder characterized by severe neutropenia, a defective marrow release mechanism, and hypogammaglobulinemia. , 1990, The American journal of medicine.
[28] C. Krill,et al. CHRONIC IDIOPATHIC GRANULOCYTOPENIA. , 1964, The New England journal of medicine.
[29] W. Zuelzer,et al. "MYELOKATHEXIS"--A NEW FORM OF CHRONIC GRANULOCYTOPENIA. REPORT OF A CASE. , 1964, The New England journal of medicine.